ClinicalTrials.gg
WithdrawnNCT03932318Updated Jul 20, 2023

Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients

A Phase 1/2 interventional study of Lintuzumab-Ac225 and Venetoclax in Acute Myeloid Leukemia and Relapsed Adult AML, sponsored by Actinium Pharmaceuticals. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-20.

Sponsored by Actinium Pharmaceuticals · Phase 1/2, Interventional, and Treatment

How we know

Why this study was withdrawn
study postponed

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 203 studies testing venetoclax in Leukemia, Myeloid, Acute — 116 open to participants now, 145 under way, 22 of them phase 3. venetoclax · Leukemia, Myeloid, Acute.

Enrollment
200th of 203
0 · median 58
Started
2023
with 15 others
Phase 1/2
28 of 203
12 open now
Registered
33rd of 203
by date

Among the 203 studies testing venetoclax in Leukemia, Myeloid, Acute, this one is the 200th largest by enrollment, is one of 16 that started in 2023, is one of 28 in phase 1/2, and was the 33rd registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

116 of the 203 studies testing venetoclax in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:

111 more — sign in →

By country, each count listing its studies:

All 116 open studies →

About venetoclax

venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 203 studies testing venetoclax in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

The study is a multicenter, open label Phase I/II trial.

  1. To determine the maximum tolerated dose (MTD) of lintuzumab-Ac225 when given in combination with venetoclax and azacitidine for patients with CD33 positive AML. (Phase I portion)
  2. To assess the percentage of patients with CR, CRh, CRi, MLFS or Overall Response (CR + CRh + CRi + MLFS), up to 6 months after the start of treatment without receiving other AML therapies.. (Phase 2 portion)
Read the detailed description

The study is a multicenter, open label Phase I and Phase II trial combining lintuzumab-Ac225 with venetoclax and azacitidine in patients who have relapsed or refractory AML.

The Phase I portion is a dose-finding study which will enroll at least three patients at each dose level. Patients in each dose level will be observed for a minimum of 4 weeks before dose escalation occurs. There is no dose escalation for any individual patient. Lintuzumab-Ac225 is administered on Day 8 of the first 4 treatment cycles.

The Phase II portion of the study will enroll patients at the MTD dose level of lintuzumab-Ac225 as determined in the Phase I portion of the study. The goal of the Phase II portion will be to further characterize the safety and efficacy of the MTD dose of lintuzumab-Ac225.

03

Conditions studied

  • Acute Myeloid Leukemia
  • Relapsed Adult AML

Keywords

  • Lintuzumab-Ac225
  • Venetoclax
  • Azacitidine
  • Lintuzumab
  • Refractory AML
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed acute myeloid leukemia
  2. or relapsed AML which will include:

    1. Refractory disease will be defined as at least 1 prior treatment with no remission.
    2. Relapsed disease will be defined as 5% or more blasts in bone marrow seen after remission.
    3. Patients with AML arising from myelodysplastic syndromes (including CMML) or myeloproliferative neoplasms (secondary AML, ts-AML) are also eligible.
  3. White blood cell (WBC) count \< 10 x 109/L;

    a. Use of hydroxyurea, prior to Cycle 1 and during Cycles 1 and 2, is permitted to lower the WBC count in the peripheral blood.

  4. Age > 18 years.
  5. Estimated ≥ 50 mL/min calculated by the Cockroft-Gault formula.
  6. and ALT ≤ 3.0 x (unless considered to be due to leukemic organ involvement).
  7. ≤ 3.0 x ULN (unless considered to be due to leukemic organ involvement).
  8. (ECOG) Performance Status ≤ 2.

Exclusion criteria

Exclusion Criteria:

  1. Have acute promyelocytic leukemia (APL).
  2. Active CNS leukemia. Patients with symptoms of CNS involvement, particularly those with M4 or M5 subtypes, should undergo lumbar puncture prior to treatment on study to exclude CNS disease. Symptoms include cranial neuropathies, other neurologic deficits, and headache.
  3. Have received prior radiation to maximally tolerated levels to any critical normal organ.
  4. Participant has received strong and/or moderate inducers within 7 days prior to the initiation of study treatment.
  5. cardiac disease.
  6. Active, uncontrolled serious infection.
  7. Have other non-myeloid within 2 years of entry (with exceptions).
  8. Psychiatric disorder that would preclude study participation
  9. Previous solid organ transplant (prior treatment with SCT is allowed but not if patient as or is still receiving /GVHD therapy).
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Phase I and Phase II

    Lintuzumab-Ac225 will be administered on Day 8 of each cycle for four cycles (unless in the 0.5 μCi/kg or 0.25 μCi/kg cohorts, where there is a potential for an additional four cycles, pending PI and Medical Monitor review). Venetoclax will be taken on Days 1-21 of each cycle for up to 12 cycles. Azacitidine will be administered on Days 1-7 of each cycle for up to 12 cycles. Each cycle is 28 days, with a potential to expand to 42 days to allow for full hematologic recovery.

    Biological: Lintuzumab-Ac225 · Drug: Venetoclax · Drug: Azacitidine

Interventions

  • BiologicalLintuzumab-Ac225

    In the Phase I, patients will be enrolled into the following dose escalation cohorts: 0.50 μCi/kg, 1.0 μCi/kg, and 1.5 μCi/kg. If the 0.50 μCi/kg dose is determined to exceed the MTD, a 0.25 μCi/kg dose will be explored.

    Also known as: Actimab

  • 400 mg daily will be taken orally on Days 1-21 of a 28-day cycle. There will be a ramp up of venetoclax dosing in the first cycle, with 100 mg administered on Day 1, 200 mg on Day 2, and 400 mg on Day 3 and Day 4 and later. Patients on antifungal azoles should receive one-half these doses, up to a maximum of 200 mg of venetoclax.

    Also known as: Venclexta

  • 75 mg/m2 will be administered on days 1-7 of a 28-day cycle.

    Also known as: Vidaza

06

What researchers measure

Primary outcomes

  1. Phase I: Maximum Tolerated Dose (MTD) of Lintuzumab-Ac225

    To determine the maximum tolerated dose (MTD) of lintuzumab-Ac225 when given in combination with venetoclax and azacitidine for patients with CD33 positive AML

    Time frame: Cycle 1, up to 48 days

  2. Phase II: Overall Response (CR + CRh + CRi + MLFS)

    To assess the percentage of patients achieving CR, CRh, CRi, morphologic leukemia-free state (MLFS), or Overall Response (CR + CRh + CRi + MLFS), up to 6 months after the start of treatment without receiving other AML therapies

    Time frame: Up to 6 months

Secondary outcomes

  1. Phase I: Overall Response

    Number of patients who's overall response is CR or CRh or CRi or MLFS

    Time frame: Up to 6 months

  2. Phase I: OS

    Number of patients who died

    Time frame: Phase I: End of 6 months, 12 months, 24 months.

  3. Phase II: OS

    Number of patients who died

    Time frame: Phase II: End of 6 months, 12 months, 24 months

  4. Phase I and II: DFS

    Disease-free survival

    Time frame: Through study completion, up to 2 years

  5. Phase I and II: Evaluate incidence of AEs and SAEs

    Rate of AEs and SAEs, including infusion-related reactions

    Time frame: Through study completion, up to 2 years

  6. Phase I and II: Lab abnormalities (other than hematologic indices)

    Summary of rate of Grade 3/4 lab abnormalities

    Time frame: Through study completion, up to 2 years

  7. Phase I and II: Evaluate BH3 priming assay results

    Summary of assay results

    Time frame: Completion of Cycle 1, estimated 1 month

  8. Phase I and II: MRD status

    Number of patients who are MRD negative

    Time frame: From date of first dose until the date of first documented response, first assessment at 6 months

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2023; primary completion for Dec 2023, 9 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2019
First posted
Apr 30, 2019
StartEst.
Mar 2023
Primary completionEst.
Dec 2023
CompletionEst.
Sep 2024
Last update
Jul 20, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03932318
Lead sponsor
Actinium Pharmaceuticals
Responsible party
Sponsor
First posted
Apr 30, 2019
Start date
Mar 2023 (estimated)
Primary completion
Dec 2023 (estimated)
Completion
Sep 2024 (estimated)
Last update
Jul 20, 2023

Study contacts

Avinash Desai, MD
study chair · Actinium Pharmaceuticals, Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Venetoclax · Azacitidine

Start the discussion